FDA Said to Approve Expanded Indication for Janssen's (JNJ) Zytiga
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) Janssen Bioscience is said to have gotten an expanded indicating for its late-stage prostate cancer drug, Zytiga. Headlines come from Bloomberg this afternoon.
Johnson & Johnson shares are positive on the session Monday.
Johnson & Johnson shares are positive on the session Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Raymond James sees token pricing gap widen in August 2026
- UBS says bull market has further to run
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
